Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555285 | 0.83 | CYP1A2 (0.37) | CYP2D6CA1CA7CA2NR1D1 | |
| SCHEMBL19458 | 0.80 | TDP1 (0.42) | CYP2D6TDP1EYA2APPACE | |
| SCHEMBL8777319 | 0.80 | TDP1 (0.41) | CYP2D6TDP1EYA2APPACE | |
| SCHEMBL8388793 | 0.79 | KDM4E (0.32) | MEN1GAAKMT2ATDP1KDM4E | |
| SCHEMBL5033034 | 0.79 | MEN1 (0.34) | MEN1GAAKMT2A | |
| SCHEMBL8719360 | 0.79 | CASR (0.30) | CYP2D6NR1D1 | |
| SCHEMBL8061701 | 0.78 | NR1D1 (0.31) | TDP1EYA2APPACENR1D1 | |
| SCHEMBL14439275 | 0.78 | NR1D1 (0.31) | TDP1EYA2APPACENR1D1 | |
| SCHEMBL3844876 | 0.78 | EPOR (0.33) | MEN1GAAKMT2ATDP1EYA2 | |
| SCHEMBL4621864 | 0.78 | TDP1 (0.58) | TDP1EYA2APPACECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211241-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-6861043-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2002-12-12 | — | — | US | disclosed |
| US-6426059-B1 | NUCLEAR MAGNETIC RESONANCE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-07-30 | — | — | US | disclosed |
| EP-0836485-B1 | CASCADE POLYMER COMPLEXES | SCHERING AG (DE) | 2002-07-24 | — | — | EP | disclosed |
| US-6177060-B1 | NMR OR X-RAY LYMPHOGRAPHY IMAGES | SCHERING AKTIENGESEUSCHAFT (DE) | 2001-01-23 | — | — | US | disclosed |
| US-6166200-A | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| US-6063361-A | ADMINISTERING TO A PATIENT AT LEAST ONE CASCADE POLYMER COMPLEX AND SUBJECTING THE PATIENT TO A RADIOLOGY DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| US-5820849-A | DIAGNOSIS WITH NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-10-13 | — | — | US | disclosed |
| EP-0836485-A2 | CASCADE POLYMER COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002051-A2 | CASCADE POLYMER COMPLEXES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | ZYX, CCNY, MOK | CYP2D6 2199/4885MEN1 2533/4885GAA 3241/4885 |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | TFPI, LYN, SYK | CYP2D6 2681/4885MEN1 760/4885GAA 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.